LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents


LUCA Science, a company developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs, today announced the closing of a $9.8 million Series A financing. The funding round was led by Axil Capital Partners. Additional participating investors included Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC.

This press release features multimedia. View the full release here:

LUCA Science Inc. (Graphic: Business Wire)

Background of the fundraise and future prospects

LUCA Science is a preclinical stage*1 biopharmaceutical company focusing on the discovery of novel mitochondria therapy to treat diseases and injuries in multiple therapeutic areas.

Mitochondria are the power plants in our cells that produce energy for our bodies. These small intracellular organelles house cellular aerobic respiration, the process used to turn oxygen and nutrients into energy. Recent research has shown that supplying highly functional mitochondria to injured tissues

Read More